Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children

Status: Recruiting
Phase: Phase 3
Diagnosis: Breast: Prevention
NCT ID: NCT00685256 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 07-406

 

RATIONALE: A study that evaluates the support of a decision guide used together with genetic counseling may improve communication between mothers undergoing BRCA1/2 testing and their minor-age children. PURPOSE: This randomized phase III trial is studying standard genetic counseling given together with a decision guide to see how well it works compared with genetic counseling alone in improving communication between mothers undergoing BRCA1/2 testing and their minor-age children.

 

Conducting Institutions:
Dana-Farber Cancer Institute, Children's Hospital Boston

Overall PI:
Andrea Patenaude, MD, Dana-Farber Cancer Institute

Site-responsible Investigators:

Contacts:
Dana-Farber Cancer Institute: Andrea Patenaude, 617-632-3314, andrea_patenaude@dfci.harvard.edu

Eligibility Criteria

DISEASE CHARACTERISTICS: - Mothers self-identified as primary caregivers to minor-age children (ages 8-21 years-old) - Mothers must be undergoing genetic counseling and have provided a blood sample for analysis for BRCA1/2 mutations - Mothers must have resided in the same home as the child(ren) for the past 6 months and intend to continue to reside with the child(ren) for the next 6 months PATIENT CHARACTERISTICS: - At least 21 years old (mothers) - No serious mental illness (e.g., cognitive and psychotic disorders) or developmental disability that would limit participation or preclude informed consent - Must be able to adequately understand, speak, and read English - Must have ready and consistent access to a telephone PRIOR CONCURRENT THERAPY: - Not specified
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms